IOVA News and Press, Iovance Biotherapeutics Inc. From 05/25/24

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leaders...

Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate ...

2024-05-13 11:06:56 ET Summary Iovance's new TIL therapy, Amtagvi, has launched but with modest Q1 revenue amidst substantial operational costs. Enrollment has reached over 100 patients, showing a promising start, although logistical challenges persist. Financially, Iovance ha...

2024-05-11 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always lo...

2024-05-10 14:40:31 ET Summary Iovance Biotherapeutics reported its Q1 2024 earnings yesterday. The company made a net loss of $(113m), or $(0.42) per share. Iovance secured a historic approval for a first solid tumor targeting cell therapy in mid-Feb, triggering overnight gains o...

2024-05-10 14:03:28 ET Iovance Biotherapeutics (NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk response to the news, ho...

2024-05-09 20:40:27 ET Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Results Conference Call May 09, 2024 04:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communications Dr. Fred Vogt - Interim President &...

2024-05-09 16:03:02 ET More on Iovance Biotherapeutics Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results Iovance Biotherapeutics: Initial Amtagvi Launch In Focus Iovance Biotherapeutics, Inc. (IOVA) Q4 2023 Earnings Call Transcript ...

Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year...